Trial results from the NOLA (NeuWave Observational Liver Ablation) Registry for Liver Cancer were posted on 2026-04-17, detailing outcomes for 1254 enrolled participants.
Background
Liver cancer remains a significant global health challenge, often requiring localized treatment options, especially for patients who are not candidates for surgery. Microwave ablation is a minimally invasive procedure used to destroy cancerous tumors within the liver using heat. Observational registries like NOLA play a crucial role in collecting real-world data on the effectiveness and safety of such procedures in a broad patient population, complementing data from controlled clinical trials.
Trial design
The NOLA Registry, a multicenter, observational study, enrolled 1254 participants with conditions including Cancer of the Liver, Liver Cancer, and Neoplasms, Liver. The registry followed patients for up to 5 years after their first liver ablation procedure using the NEUWAVE Microwave Ablation System. The study was designed to observe real-world outcomes following this intervention, without a specified phase or comparator arms.
Key results
Key measurements from the NOLA Registry provide insights into the performance of microwave ablation for liver cancer:
- Number of Patients Whose Ablation Resulted in Technical Success: 1174 participants and 24 participants.
- Number of Patients Whose Ablation Resulted in Technique Efficacy: 1000 participants and 53 participants.
- Target Lesion Recurrence Rate (Percent Probability, with 95% Confidence Interval as the reported dispersion type):
- 4.69 percent
- 10.05 percent
- 14.36 percent
- 17.14 percent
- 19.94 percent
- 21.44 percent
- 25.52 percent
- 27.42 percent
What this means
The results from the NOLA Registry offer valuable real-world data on the application of the NEUWAVE Microwave Ablation System for liver cancer. The reported high numbers for technical success and technique efficacy suggest that the procedure is frequently performed effectively in a clinical setting. The various target lesion recurrence rates provide a spectrum of outcomes, likely reflecting different follow-up periods or patient subgroups, though specific details are not provided in the posted data. This observational data contributes to the understanding of microwave ablation's performance outside of controlled trial environments, informing clinicians about expected outcomes in diverse patient populations.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04107766, titled "NOLA (NeuWave Observational Liver Ablation) Registry", were posted on 2026-04-17 on clinicaltrials.gov.